GBW-White Biotech Research. Deliver high quality, accurate and timely data to support R&D, Pilot Plant and QC to hit their project targets and troubleshoot…From BASF – Thu, 20 Oct 2016 18:23:52 GMT – View all San Diego jobs
GBW-White Biotech Research. Deliver high quality, accurate and timely data to support R&D, Pilot Plant and QC to hit their project targets and troubleshoot…From BASF – Thu, 20 Oct 2016 18:23:52 GMT – View all San Diego jobs
We are seeking an individual to join our Chemistry production team and a candidate for our Oligonucleotide production team.
This position requires a minimum of two years laboratory experience.
A Bachelor’s of Science in a scienti […
A position is available at the La Jolla Institute for Allergy and Immunology in the research group of Dr. Catherine Hedrick to perform bioinformatics research in immunology in the fields of cancer and atherosclerosis. The project will include analysi […
5+ year working experience in pharmaceutical or biotech industry. Provide technical leadership to support successful delivery of technical solutions following…From Indeed – Thu, 20 Oct 2016 13:29:20 GMT – View all San Diego jobs
For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today…
[[Click headline to continue reading.]]
Study Results Presented at the 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance with Biocept’s ctDNA Liquid Biopsy Platform vs. Tissue Biopsy
Target Selector(TM) platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients
SAN DIEGO, Oct. 20, 2016 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide information to physicians to improve cancer treatment, announces that clinical results from a study evaluating 40 patients with advanced non-small cell lung cancer (NSCLC) demonstrated up to 90% concordance between the Company’s Target-Selector™ platform and tissue biopsy for the detection of actionable oncogene mutations and other validated cancer biomarkers. Analysis of a patient subset in the study showed that changes in both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), detected using Biocept’s proprietary liquid biopsy assays, correlated significantly to response to systemic drug therapy in a majority of cases. The clinical data were presented at the 2016 European Society for Medical Oncology (ESMO) Annual Congress in Copenhagen, Denmark.
“In this dataset, Biocept’s blood-based ctDNA assay demonstrated high concordance relative to tissue biopsy for the identification of actionable molecular alterations associated with non-small cell lung cancer,” stated Oscar Arrieta, M.D., the study’s lead investigator, and Coordinator of Clinical Lung Cancer and Thoracic Tumor and Head of the Laboratory of Personalized Medicine at the National Cancer Institute of Mexico. “Given these findings, the Target Selector™ technology appears to be a viable noninvasive alternative for establishing mutational status, and for identifying secondary resistance mutations such as EGFR T790M in patients who progress on first-line tyrosine kinase inhibitor therapy. Clear changes observed in the level of detectable mutant allele frequency after treatment suggest that this liquid biopsy method holds promise to be used for real-time monitoring of patients’ clinical status.”
In the study, analysis with Biocept’s Target Selector™ ctDNA platform found that the T790M resistance mutation was present in the plasma of 50% of patients with clinical progression when treated with tyrosine kinase inhibitors.
“These study results validate the ability of our Target Selector™ tests to comprehensively profile a patient’s cancer, and further demonstrate the high sensitivity and specificity of our dual ctDNA and CTC assay platforms,” said Biocept’s Senior Vice President and Chief Scientific Officer, Lyle Arnold, Ph.D.
“We are pleased that these findings, generated by world-class collaborators from both academia and biopharma, were presented at the Annual ESMO Congress in Copenhagen,” said Biocept’s President and CEO Michael Nall. “We continue to build the body of clinical evidence supporting the utility of our proprietary liquid biopsy platform, as we increase physician adoption of our technology and help patients in their fight against cancer.”
Physicians interested in ordering Biocept’s liquid biopsy tests for cancer biomarkers should contact Customer Service at 858-320-8206, or visit http://biocept.com/medical-professionals/.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and ctDNA. With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, our liquid biopsy platform being a viable noninvasive alternative for establishing mutational status and for identifying secondary resistance mutations, our liquid biopsy platform being capable of proving real-time monitoring of patients’ clinical status, and our ability to increase physician adoption of our technology, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.
SOURCE Biocept, Inc.
Theler, of Freeform TV’s “Baby Daddy,” Has Type 1 Diabetes and is Sharing His Success with Life-Changing Continuous Glucose Monitoring
SAN DIEGO, Oct. 20, 2016 /PRNewswire/ — Dexcom, Inc., (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today it has partnered with Derek Theler of Freeform’s “Baby Daddy,” who has type 1 diabetes, to raise awareness of the benefits of CGM for people with the disease. Theler, who has been nominated for two Teen Choice Awards, will share his personal story and views on living with diabetes and his use of Dexcom technology to help him monitor his glucose levels and manage his diabetes while he pursues and lives his dreams. Through the collaboration with Dexcom, Theler hopes to spread awareness for CGM and provide encouragement for those impacted by diabetes to take control of the disease and continue to do the things they enjoy.
With approximately 29.1 million Americans living with diabetes, education on disease management is crucial to living with the condition day-to-day.1 The growth of continuous glucose monitoring systems, like the Dexcom G5® Mobile CGM System, has helped patients with both type 1 and type 2 diabetes understand valuable information about their glucose levels and trends, a key aspect to controlling the disease and staying healthy.
“Whether I’m shooting a film in South Africa or on the set in LA, being an actor means having a career that is intensely physical and constantly changing, and it’s nearly impossible to keep a regular routine,” said Theler. “The Dexcom CGM has allowed me to navigate my blood sugar’s highs and lows so I can work without interruption. It also gives my mom peace of mind, because she can use the Dexcom Follow app to easily check on me when I’m traveling and filming. CGM has made me feel safe and has transformed my life and career in invaluable ways.”
Both Theler and his sister Ashlea were diagnosed with type 1 diabetes as young children. As a kid he felt having diabetes was difficult to live a normal childhood. Over the years, diabetes strengthened Theler’s motivation to pursue his dreams and to share his story to inspire others to realize that they too can live out their passions with diabetes especially with the right tools and support to help manage the condition. With dedication and a strong spirit, Theler earned a degree in pre-med from Colorado State University before moving to LA to pursue his dream of becoming an actor. Now, an advocate for others living with diabetes, Theler is committed to spreading the word about disease management, and how to live life without limitations.
“We are excited to be collaborating with Derek Theler on this educational campaign,” stated Kevin Sayer, Chief Executive Officer of Dexcom. “As someone who has truly benefited from CGM, Derek’s support in raising further awareness for management options and living life to the fullest with diabetes will augment our ongoing efforts to educate people about how they can best manage their diabetes. We believe Derek’s story will help inspire those who struggle with this disease on a daily basis.”
Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years.2 The traditional standard-of-care for glucose (blood sugar) monitoring has been a finger stick meter. CGM augments the use of glucose meters for the management of diabetes. With the recent introduction of the Dexcom G5 Mobile CGM System, people with diabetes can now view their glucose information on their iOS-enabled devices for real-time diabetes management. CGM is important because, in addition to indicating the glucose level, it provides the direction and rate of glucose change with the push of a button and alerts users when glucose is too low or too high.
Diabetes affects 10% of the American population and is the 7th leading cause of death in the United States.1 With diabetes, the body cannot produce or use the hormone insulin effectively, causing a buildup of glucose, or sugar, in the blood. It is estimated that approximately 86 million Americans over the age of 20 are at risk for developing diabetes (primarily Type 2), largely due to obesity, physical inactivity and poor diet.1 People with diabetes who take insulin must monitor their blood glucose levels frequently. Uncontrolled glucose can cause health complications and even death.3,4
About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.
About Derek Theler
Derek Theler is a 30-year-old actor from Colorado living with Type 1 Diabetes. After earning a degree in pre-med from Colorado State University, in 2009, Derek moved to LA to begin his acting career. After a couple supporting TV roles on series such as “The Middle” and “Cougar Town”, he quickly landed is his first major role as “Danny Wheeler” on the hit Freeform series, “Baby Daddy.” Theler has also starred in the action-thriller digital series “Project S.E.R.A.”. Derek has been nominated for two Teen Choice Awards. Derek currently lives in Los Angeles. For more on Derek, please visit his pages on Facebook and Instagram.
To view multimedia assets, please visit: http://www.multimedianewscenter.com/dexcom/dexcom-media-portal.
1. Diabetes.org (http://www.diabetes.org/diabetes-basics/statistics/)
2. Clarke SF and Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus.
Br J Biomed Sci. 2012;(3)2:83-93.
3. Hyperglycemia (High blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html. Updated August 5, 2013. Accessed December 3, 2013.
4. Hypoglycemia (Low blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html. Updated July 16, 2013. Accessed December 3, 2013.
SOURCE Dexcom, Inc.
MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA
Trial to Support China NDA Filing for MRX-I
HAYWARD, Calif. and SHANGHAI, Oct. 20, 2016 /PRNewswire/ — MicuRx Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a pivotal Phase 3 study of MRX-I in China for the treatment of complicated skin and skin structure infections (cSSSI). These infections are frequently caused by multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRX-I is an oral, next generation oxazolidinone antibacterial targeting infections due to drug resistant Gram-positive bacteria, including MRSA and vancomycin-resistant enterococci (VRE).
“The recent $55M Series C financing will allow MicuRx to complete this Phase 3 study and file a New Drug Application for MRX-I in China, in addition to clinical milestones in the complementary U.S. clinical program. The initiation of this study is a significant milestone for MicuRx, as well as for the antibiotic field at large,” said Zhengyu Yuan, Ph.D., president and CEO of MicuRx. “Antibiotic resistance to current therapies is at an all-time high. According to the Centers for Disease Control in the U.S., over two million people are infected with bacteria resistant to antibiotics every year and tens of thousands die annually.1 New oral treatments are desperately needed, and MRX-I may well meet this medical need.”
The MicuRx Phase 3 study will enroll 600 patients with cSSSI at more than 40 centers in China. Evaluation in two randomized groups of patients will compare 800 mg of oral MRX-I to 600 mg of oral linezolid (Zyvox®). Patients will be treated for seven to 14 days, with a follow up observation period up to 14 days to ensure clearance of the infection and to monitor side effects. Results are expected in early 2018.
Currently, most anti-MRSA agents for serious infections are available only intravenously (IV). According to two independent market research reports based on physician surveys, an oral, anti-MRSA antibiotic that is safe for patients with co-morbidities, especially for use longer than 10 days, remains an important unmet medical need.2,3
“We are developing a better tolerated, oral antibiotic for patients and healthcare providers that will allow more convenient and affordable therapy of drug-resistant Gram-positive bacterial infections, potentially reducing hospitalization and inconvenient drug administration required for IV-only antibiotics,” commented Barry Hafkin, M.D., chief medical officer of MicuRx. “With the recent policy change in China, oral antibiotics for MRSA are preferred to allow for patients to be treated in the community instead of receiving an IV in the hospital.”
In 2015, MicuRx successfully completed two independent Phase 2 studies for MRX-I in China and the U.S. Both Phase 2 trials, as well as completed Phase 1 studies in China, Australia, and the U.S. demonstrated that MRX-I is highly efficacious with non-inferiority to linezolid in treatment of skin infections, and with markedly-reduced hematologic toxicity compared to oral linezolid.
About Methicillin-Resistant Staphylococcus Aureus (MRSA)
MRSA is the world’s most common human drug-resistant bacterial pathogen, responsible for millions of infections and tens of thousands of deaths worldwide in a wide variety of infections such as skin, bone, lung, and bloodstream. While several antibiotics with activity against MRSA are marketed, very few oral agents against this pathogen are available. New oral treatment options with an improved safety profile are needed for the outpatient therapy, as well as for broadly preferred transition from intravenous to oral therapy providing maximum convenience to patients and minimizing the hospitalization time and cost.
About MicuRx Pharmaceuticals, Inc.
MicuRx (http://www.micurx.com/) is a privately-held biopharmaceutical company whose mission is to discover and develop antibiotics with improved safety profiles to improve the treatment of resistant bacterial infections. The lead compound, MRX-I, a next-generation oxazolidinone targeting methicillin resistant S. aureus (MRSA), was structure-designed to reduce hematological adverse events of this antibiotic class. In 2015, MicuRx completed two independent Phase 2 studies in the US and China for MRX-I, and has initiated Phase 3 in China in complicated skin and skin structure infections (cSSSI). The company has research and development facilities outside San Francisco, CA in the United States, and in Shanghai, China. The company has raised a total of $92 million through leading venture capital firms including Morningside Ventures, BVCF, GP Healthcare Capital, GP TMT Capital, 3E Bioventures Capital, and Delian Capital. Visit www.micurx.com for more information.
- Antibiotic Resistance Threats Report, 2013. Centers for Disease Control and Prevention, https://www.cdc.gov/drugresistance/
- Disease Landscape & Forecast, Methicillin-Resistant Staphylococcus Aureus’. January 2016. Report by Decision Resource Group
- BioTrak Research, Quantitative Market Study with US Infectious Disease Physicians, 2016
SOURCE MicuRx Pharmaceuticals, Inc.
SAN DIEGO, Oct. 20, 2016 /PRNewswire/ — Molecular Assemblies Inc., a company developing a proprietary enzymatic DNA synthesis technology designed to power the next generation of DNA-based products, today announced the appointment of Michael J. Kamdar as CEO and director. Mr. Kamdar brings 25 years of highly successful biotechnology leadership and transaction experience to his new role.
On behalf of the board of directors, Chairman Larry Stambaugh said, “We are honored to have Mr. Kamdar join the Molecular Assemblies team. He has represented some of the most successful life science companies in the community and his leadership, commercialization and financing experience will be invaluable to Molecular Assemblies as we build a dominant and leading company in the next generation of genomics.”
Kamdar comes to Molecular Assemblies with more than 25 years of domestic and international pharmaceutical and biotechnology leadership experience as founder, board member and senior executive of notable pharmaceutical and biotechnology companies, including Agouron Pharmaceuticals, Warner-Lambert, Pfizer, Anadys Pharmaceuticals, VentiRx Pharmaceuticals, Tobira Therapeutics and Ciclofilin Pharmaceuticals. In these roles, Kamdar successfully raised hundreds of millions of dollars to fund development and commercialization of pharmaceutical products and completed numerous strategic and corporate transactions totaling more than $1 billion.
“I am pleased to join the outstanding team at Molecular Assemblies, including founders Dr. William Efcavitch and Curt Becker, who have lead the development of the company’s radical new approach to DNA synthesis and put Molecular Assemblies at the forefront of powering a new generation of DNA-based products,” Kamdar said. “Molecular Assemblies’ patented enzymatic process for writing genetic code promises to enable and accelerate all areas of genomic applications from industrial synthetic biology, gene and cell-based therapeutics and precision diagnostics, to the exploitation of the amazing properties of DNA beyond biology such as data information storage, nanomachines, and bio-based electronics. l am particularly enthusiastic about advancing and commercializing this transformative technology.”
Molecular Assemblies was founded in 2013 by Efcavitch and Becker, who developed the current chemical process for DNA synthesis as early founders of Applied Biosystems. Recognizing the constraints and limitations to the chemical process, Efcavitch and Becker sought to develop a new method of DNA synthesis based on the way nature makes DNA. This enzymatic approach produces long, high quality, sequence-specific DNA, reliably, affordably and sustainably, and overcomes the limitations of traditional chemical DNA synthesis, which is error prone, time-consuming and unscalable.
“Speaking for the rest of the team at Molecular Assemblies, we are very pleased to have Mike joining us in this exciting endeavor. He brings skills and experience that complement that of the founders. Molecular Assemblies now has all of the necessary elements to take a leadership role in making DNA the industrial polymer of the 21st Century,” Efcavitch said.
About Molecular Assemblies
Molecular Assemblies Inc. is a San Diego-based company focused on developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines and bio-based electronics. Molecular Assemblies was founded in 2013 by William Efcavitch PhD, and Curt Becker, who pioneered the chemical DNA synthesis approach used today. For more information please visit http://www.molecularassemblies.com.
CEO Michael Kamdar
SOURCE Molecular Assemblies Inc.